(UroToday.com) Dr. Shilpa Gupta discussed the prior three abstracts in the context of a conundrum in first-line treatment of advanced urothelial carcinoma – are more drugs beyond platinum chemotherapy always better? She began her discussion with a timeline of approvals over the past several decades, focusing on the initial approvals of immunotherapy in 2016.
(UroToday.com) Given multiple lines of evidence supporting the efficacy of immunotherapy in urothelial cancers, there is interest in identifying therapeutic strategies that can augment patient outcomes. The Inducible T-cell co-stimulator (ICOS) protein is a member of the CD28 immunoglobulin receptor superfamily, which is the same receptor superfamily that CTLA-4 and PD-1 belong to. ICOS is expressed […]
(UroToday.com) The KEYNOTE-052 study led to the approval of pembrolizumab for the first-line treatment of cisplatin-ineligible patients with advanced urothelial carcinoma. In this presentation, Dr. Peter O’Donnell presented updated results of 5 years of follow-up, with the median time from enrollment to data cutoff of 56.3 months.
(UroToday.com) The 2021 American Society of Clinical Oncology (ASCO) annual meeting’s urothelial carcinoma oral abstract session featured a discussant presentation by Dr. Shilpa Gupta discussing conundrums in first-line urothelial carcinoma.
(UroToday.com) There have been transformational changes in first-line therapy for patients with metastatic renal cell carcinoma (RCC) in the past three years. Foremost among these is the move from monotherapy to combination approaches. While CheckMate 214 first brought combination therapy with dual checkpoint inhibition (nivolumab and ipilimumab) to the forefront, subsequent studies have examined combinations of […]
(UroToday.com) While there have been transformational changes in first-line therapy for patients with advanced renal cell carcinoma (RCC) in the past three years, these studies have focused on patients with clear cell histology. As a result, there have been little direct data to guide care for patients with non-clear cell histologies (nccRCC) and we have had […]
To compare laparoscopic partial nephrectomy (LPN) and robot-assisted partial nephrectomy (RAPN) performed in two European tertiary centers using the classic optimal surgical definition – "MIC" – and a new optimal surgical definition: the "Novel TRIFECTA" (NT) concept.
Guidelines endorse using tumor risk and life expectancy (LE) to select appropriate candidates for radical prostatectomy (RP), recommending against treatment of most low-risk tumors and men with limited LE.
The European Association of Urology guideline for upper tract urothelial carcinoma (UTUC) relies on two grading system: 1973 World Health Organization (WHO) and 2004/2016 WHO. No consensus has been made which classification should supersede the other and both are recommended in clinical practice.
Despite recent advances, treatment options for men with metastatic castration-resistant prostate cancer (mCRPC) progressing after next-generation hormonal agents (NHAs) are limited and provide only modest survival benefit.
